Laurens A. Van Kleef

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Reply to Jiang et al.

Reply to Jiang et al.

Journal: The American journal of gastroenterology

Published: July 22, 2026

Urinary Volatile Organic Compound Metabolites Are Associated With MASLD/MASH in Humans and Induce Steatosis in Liver Organoids.

Urinary Volatile Organic Compound Metabolites Are Associated With MASLD/MASH in Humans and Induce Steatosis in Liver Organoids.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 23, 2026

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Journal: Gastroenterology

Published: March 09, 2026

Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population.

Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population.

Journal: Gastro hep advances

Published: January 26, 2026

Liver stiffness dynamics in European populations (LiverScreen): a longitudinal, multicentre, prospective, population-based cohort study.

Liver stiffness dynamics in European populations (LiverScreen): a longitudinal, multicentre, prospective, population-based cohort study.

Journal: The lancet. Gastroenterology & hepatology

Published: January 05, 2026

Delphi survey to explore core curriculum for training the next-generation of hepatologists☆.

Delphi survey to explore core curriculum for training the next-generation of hepatologists☆.

Journal: JHEP reports : innovation in hepatology

Published: December 10, 2025

Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Journal: Drug design, development and therapy

Published: December 08, 2025

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

Journal: Hepatology communications

Published: December 03, 2025

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

Journal: Hepatology communications

Published: December 03, 2025

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Journal: Lancet (London, England)

Published: September 17, 2025

Underuse of statins in MASLD despite population-based associations with lower liver stiffness.

Underuse of statins in MASLD despite population-based associations with lower liver stiffness.

Journal: JHEP reports : innovation in hepatology

Published: September 08, 2025

Reply: Concerns regarding the diagnostic utility of non-invasive tests for clinically significant liver disease.

Reply: Concerns regarding the diagnostic utility of non-invasive tests for clinically significant liver disease.

Journal: Hepatology (Baltimore, Md.)

Published: September 04, 2025

Showing 1-12 of 66

Last Updated: 09/26/2026